InChIKey	DDOOFTLHJSMHLN-ZQHRPCGSSA-N
Canonical SMILES	C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	2
Pfam Stratification	Cross-Family
Avg pChEMBL	10.17
Source	ChEMBL;BindingDB

DrugBank ID	DB15328
Drug Name	Ubrogepant
CAS Number	1374248-77-7
Groups	approved investigational
ATC Codes	N02CD04
Description	Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.[L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.[L10959] Severa...

---

Categories: Analgesics Antimigraine Preparations BCRP/ABCG2 Substrates Calcitonin Gene-Related Peptide (CGRP) Antagonists Calcitonin Gene-Related Peptide Receptor Antagonists Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2C19 Inhibitors (weak) Cytochrome P-450 CYP2C8 Inhibitors Cytochrome P-450 CYP2C8 Inhibitors (weak) Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C9 Inhibitors (weak) Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 CYP2D6 Inhibitors (weak) Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates Nervous System OATP1B1/SLCO1B1 Inhibitors OATP1B1/SLCO1B1 Substrates OATP1B3 inhibitors OATP1B3 substrates OCT2 Inhibitors P-glycoprotein substrates UGT1A1 Inhibitors

---

Cross-references: BindingDB: 361594 CHEMBL2364638 ChemSpider: 28536135 Drugs Product Database (DPD): 23801 RxCUI: 2268216 Wikipedia: Ubrogepant ZINC: ZINC000095598454